These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23850493)

  • 1. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.
    Chen X; Zhang J; Zhang Z; Li H; Cheng W; Liu J
    Hum Pathol; 2013 Nov; 44(11):2373-84. PubMed ID: 23850493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
    Ahmed N; Abubaker K; Findlay J; Quinn M
    J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative stem cells and epithelial-mesenchymal transition revealed in sections of ovarian tumor in patients with serous ovarian carcinoma using immunohistochemistry for vimentin and pluripotency-related markers.
    Kenda Suster N; Smrkolj S; Virant-Klun I
    J Ovarian Res; 2017 Feb; 10(1):11. PubMed ID: 28231820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
    Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
    Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
    Freimund AE; Beach JA; Christie EL; Bowtell DDL
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD44 expression indicates favorable prognosis in epithelial ovarian cancer.
    Sillanpää S; Anttila MA; Voutilainen K; Tammi RH; Tammi MI; Saarikoski SV; Kosma VM
    Clin Cancer Res; 2003 Nov; 9(14):5318-24. PubMed ID: 14614016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
    Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
    Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
    Elattar A; Warburton KG; Mukhopadhyay A; Freer RM; Shaheen F; Cross P; Plummer ER; Robson CN; Edmondson RJ
    Gynecol Oncol; 2012 Jan; 124(1):142-7. PubMed ID: 22001143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 16. Kindlin-2 inhibits serous epithelial ovarian cancer peritoneal dissemination and predicts patient outcomes.
    Ren C; Du J; Xi C; Yu Y; Hu A; Zhan J; Guo H; Fang W; Liu C; Zhang H
    Biochem Biophys Res Commun; 2014 Mar; 446(1):187-94. PubMed ID: 24583125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
    Winterhoff BJ; Maile M; Mitra AK; Sebe A; Bazzaro M; Geller MA; Abrahante JE; Klein M; Hellweg R; Mullany SA; Beckman K; Daniel J; Starr TK
    Gynecol Oncol; 2017 Mar; 144(3):598-606. PubMed ID: 28111004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
    Szabova L; Bupp S; Kamal M; Householder DB; Hernandez L; Schlomer JJ; Baran ML; Yi M; Stephens RM; Annunziata CM; Martin PL; Van Dyke TA; Weaver Ohler Z; Difilippantonio S
    PLoS One; 2014; 9(4):e95649. PubMed ID: 24748377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.